Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells

Laboratory Investigation

Volumn 89, Issue 12, 2009, Pages 1355-1363

  Wang, Xinwen ^a   Liao, Dan ^a   Lin, Peter H ^a   Yao, Qizhi ^a   Chen, Changyi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antioxidant; Cholesterol efflux; Ginsenosides; HAART; Macrophage; Superoxide anion

Indexed keywords

ALLIIN; ALPHA TOCOPHEROL; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN A1; CAVEOLIN 1; CHOLESTEROL; DIDANOSINE; GINSENOSIDE RB 1; GINSENOSIDE RG 1; INDINAVIR; PROTEIN P67 PHOX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIMVASTATIN; STAVUDINE; SUPEROXIDE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CELL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; FOAM CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; MACROPHAGE; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOCYTE; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 70549097326     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2009.85     Document Type: Article

References (36)

1. UNAIDS/WHO, AIDS Epidemic Update; December 2007 http://www.unaids.org.
2. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
3. Wang X, Chai H, Yao Q, et al. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 2007;44:493-499.
4. Wang X, Mu H, Chai H, et al. Human immunodeficiency virus protease inhibitor ritonavir inhibits cholesterol efflux from human macrophage-derived foam cells. Am J Pathol 2007;171:304-314.
5. Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 2003;111:389-397.
6. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257-262.
7. Mondy K, Tebas P. Cardiovascular risks of antiretroviral therapies. Annu Rev Med 2007;58:141-155.
8. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
9. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
10. Jerico C, Knobel H, Calvo N, et al. Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy. Stroke 2006;37:812-817.
11. Fu W, Chai H, Yao Q, et al. Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression. J Acquir Immune Defic Syndr 2005;39:152-158.
12. Chai H, Yang H, Yan S, et al. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquir Immune Defic Syndr 2005;40:12-19.
13. Ohashi R, Mu H, Wang X, et al. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM 2005;98:845-856.
14. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature 1993;362:801-809.
15. Palmer AM, Murphy N, Graham A. Triglyceride-rich lipoproteins inhibit cholesterol efflux to apolipoprotein (apo) A1 from human macrophage foam cells. Atherosclerosis 2004;173:27-38.
16. Gulick R. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents. AIDS 1998;12(Suppl 3):S17-S22.
17. Fielding CJ, Fielding PE. Caveolae and intracellular trafficking of cholesterol. Adv Drug Deliv Rev 2001;49:251-264.
18. Arakawa R, Abe-Dohmae S, Asai M, et al. Involvement of caveolin-1 in cholesterol enrichment of high-density lipoprotein during its assembly by apolipoprotein and THP-1 cells. J Lipid Res 2000;41: 1952-1962.
19. Lin YC, Ma C, Hsu WC, et al. Molecular interaction between caveolin-1 and ABCA1 on high-density lipoprotein-mediated cholesterol efflux in aortic endothelial cells. Cardiovasc Res 2007;75:575-583.
20. Smart EJ, Ying Y, Donzell WC, et al. A role for caveolin in transport of cholesterol from endoplasmic reticulum to plasma membrane. J Biol Chem 1996;271:29427-29435.
21. Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006;4:e365.
22. Wassmann S, Wassmann K, Nickenig G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension 2004;44:381-386.
23. Chen J, Mehta JL. Role of oxidative stress in coronary heart disease. Indian Heart J 2004;56:163-173.
24. Mondal D, Pradhan L, Ali M, et al. HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc Toxicol 2004;4: 287-302.
25. Fiala M, Murphy T, MacDougall J, et al. HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis. Cardiovasc Toxicol 2004;4:327-337.
26. Zhou W, Chai H, Lin PH, et al. Molecular mechanisms and clinical applications of ginseng root for cardiovascular disease. Med Sci Monit 2004;10:RA187-RA192. (Pubitemid 39166444)
27. Augusti KT, Sheela CG. Antiperoxide effect of S-allyl cysteine sulfoxide, an insulin secretagogue, in diabetic rats. Experientia 1996;52:115-120.
28. Dilaveris P, Giannopoulos G, Riga M, et al. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 2007;5:227-237.
29. Meydani M. Vitamin E modulation of cardiovascular disease. Ann N Y Acad Sci 2004;1031:271-279.
30. Dong F, Zhang X, Wold LE, et al. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol 2005;145:323-333.
31. Hayashi T, Juliet PA, Miyazaki A, et al. High glucose downregulates the number of caveolae in monocytes through oxidative stress from NADPH oxidase: implications for atherosclerosis. Biochim Biophys Acta 2007;1772:364-372.
32. Mousa AS, Mousa SA. Anti-angiogenesis efficacy of the garlic ingredient alliin and antioxidants: role of nitric oxide and p53. Nutr Cancer 2005;53:104-110.
33. Wu D, Liu L, Meydani M, et al. Vitamin E increases production of vasodilator prostanoids in human aortic endothelial cells through opposing effects on cyclooxygenase-2 and phospholipase A2. J Nutr 2005;135:1847-1853.
34. Uchiyama T, Atsuta H, Utsugi T, et al. Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis 2006;188:265-273.
35. Canoy D, Wareham N, Welch A, et al. Plasma ascorbic acid concentrations and fat distribution in 19 068 British men and women in the European Prospective Investigation into Cancer and Nutrition Norfolk cohort study. Am J Clin Nutr 2005;82: 1203-1209.
36. Riccioni G, Bucciarelli T, Mancini B, et al. Antioxidant vitamin supplementation in cardiovascular diseases. Ann Clin Lab Sci 2007;37:89-95. (Pubitemid 46311004)